Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

CAR T-Cell Therapy for Lymphoma

  • CAR T-cell therapy is a promising treatment for some patients with non-Hodgkin lymphoma (NHL) that has relapsed or has not responded to other therapies (refractory). It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. The FDA has approved several CAR T-cell therapies for lymphoma. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) is one of the first centers to make the FDA-approved CAR T-cell therapies available as standard of care to patients who have not had effective treatment options. CAR T-cell therapies are FDA approved for:

    Aggressive relapsed or refractory large B-cell lymphoma including diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and transformed follicular lymphoma.

    • Yescarta (axicabtagene ciloleucel): Clinical trials of Yescarta for some forms of aggressive non-Hodgkin lymphoma showed 82 percent of patients responding to the CAR T-cell therapy, including 54 percent who had a complete response (i.e., no sign of cancer). The most recent follow-up data at a median 27.1 months after treatment showed that 39 percent of patients had an ongoing response, showing the lasting effectiveness of this therapy.
    • Kymriah (tisagenlecleucel): In the clinical trial for patients with some forms aggressive non-Hodgkin lymphoma, 53 percent responded to treatment, with 40 percent achieving a complete response (i.e., no sign of cancer).
    • Kymriah is also approved for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) up to age 25. Learn more about Kymriah for pediatric B-cell ALL.
    • Breyanzi (lisocabtagene maraleucel): In the clinical trial for patients with large B-cell lymphoma, 73 percent responded to the therapy, and 54 percent had a complete response.

    Relapsed or refractory mantle cell lymphoma

    • Tecartus (brexucabtagene autoleucel, formerly KTE-X19): In the clinical trial, 87 percent of patients responded to the therapy, and 62 percent had a complete response.

    Relapsed or refractory follicular lymphoma

    • Yescarta (axicabtagene ciloleucel): In the clinical trial, 91 percent of patients responded to Yescarta, including an estimated 74 percent of patients in a continued remission at 18 months.

    Our program also offers patients clinical trials of CAR T-cell therapy for other forms of lymphoma as well as trials of CAR T-cell therapy earlier in treatment and in combination with other immunotherapies.

    Patients are evaluated carefully to determine if this therapy is appropriate for them. Learn more about CAR T-cell therapy.


  • Caron Jacobson, MD, detailed the research that led to FDA approval of CAR T-cell therapy for mantle cell lymphoma in July 2020.

  • Dana-Farber/ Brigham and Women's Cancer Center
  • Contact Information for CAR T-Cell Therapy

    For more information about CAR T-cell therapy, please call 877-801-CART (2278).

  • Pediatric CAR T-Cell Therapy

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).


  • Caron Jacobson, MD, Medical Director of the Immune Effector Cell Therapy program, discussed the first approval of chimeric antigen receptor (CAR) T-cell therapy for certain patients with non-Hodgkin lymphoma in October 2017.